{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-383645","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2026-09-04T20:06:30+00:00","discovered_at":"2026-09-04T20:07:00.355600+00:00","generated_at":"2026-09-04T20:07:10.948671+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Intellia secures $400M non-dilutive credit facility with OrbiMed; $75M funded upfront","bullets":["$75M funded at closing; up to $325M additional tied to milestones (FDA approval of lonvo-z, revenue targets, equity raise, mutual agreement).","Interest at SOFR + 6.15% (3% floor), maturity Sept 4, 2031; secured by substantially all assets incl. IP.","Proceeds for working capital and general corporate purposes; covenants include maintaining $50M liquidity until FDA approval of lonvo-z.","Facility provides flexibility for lonvo-z launch in HAE and pipeline advancement; TD Cowen advised Intellia."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-383645","json":"https://secwatch.observer/filing/0001193125-26-383645.json","markdown":"https://secwatch.observer/filing/0001193125-26-383645.md","text":"https://secwatch.observer/filing/0001193125-26-383645.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526383645/0001193125-26-383645-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526383645/d110798d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-04T20:07:10.948671+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}